Search results for " Clinical data"
showing 3 items of 3 documents
A new tuning parameter selector in lasso regression
2019
Penalized regression models are popularly used in high-dimensional data analysis to carry out variable selction and model fitting simultaneously. Whereas success has been widely reported in literature, their performance largely depend on the tuning parameter that balances the trade-off between model fitting and sparsity. In this work we introduce a new tuning parameter selction criterion based on the maximization of the signal-to-noise ratio. To prove its effectiveness we applied it to a real data on prostate cancer disease.
Clinical features and lifestyle of patients with amyotrophic lateral sclerosis in Campania: brief overview of an Italian database
2012
Background. Physical activity and occupational exposures appeared to play a relevant role in pathogenesis of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease of unknown origin. Materials and methods. We aimed to make an overview of the clinical characteristics and life - style (occupation and sport) of a population of 395 patients with ALS from campania, in southern Italy. Results. ALS onset resulted anticipated of about 11 years in industry workers, whilst the more frequent site of onset among farmers was upper limbs. compared to non-athletes, athletes, particu- larly soccer players, showed a 7 years anticipation of ALS onset, with higher mortality after 5 years. Discussion…
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-instit…
2021
INTRODUCTION: There have been significant developments in colorectal cancer (CRC) research over the last few years, with the introduction of new agents that have been prolonged median overall survival of metastatic colorectal cancer (mCRC). These therapies have improved patient outcomes; however, despite significant progress in strategies for cancer treatment, their use is limited by development of resistant mechanism. Almost 30% of patients with refractory mCRC will remain good candidates for further treatment. Regorafenib and TAS-102 are novel antitumor agents for patients with refractory mCRC. However, it is unclear which patients may derive a survival benefit from these drugs in real-li…